A study by Aronne et al. investigated the effects of the dual GLP1/GIP receptor agonist (RA) tirzepatide in obese patients when it is administered over a longer period of therapy and the effects of discontinuation. Interesting new findings were also published on the GLP-1 RA semaglutide. McGowan et al. looked at the effects in obese patients with prediabetes, while Deanfield et al. investigated possible cardioprotective effects in obesity and comorbid atherosclerotic cardiovascular disease.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Practice Management
Improved quality of care aims for satisfied patients
- Chemsex - MSM, sex, chrystal meth & co.
Medical and psychosocial perspectives
- Bladder cancer
Tuberculosis vaccination reduces recurrences
- Oral JAK-i in atopic dermatitis
Benefits and risks: What does the current data say?
- Sleep-wake disorders in pneumology practice
Patience, knowledge and persistence in therapy
- Chronic lung diseases
Sarcopenia and malnutrition in the context of pneumological rehabilitation
- Cardiovascular risk and obesity
Pathomechanisms, secondary prevention and treatment options
- Oxidative stress and neurodegeneration